Alert detail
LCD L39940: MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis — CGS
What changed
New LCD on hereditary amyloidosis testing affects billing practices.
Who’s affected: Clinical Laboratory billing teams · Effective: March 19, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
This change affects 4 billing codes.
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.